EFFECTS OF WALNUT LEAVES EXTRACT ON EFFICACY OF DAPAGLIFLOZIN IN TYPE II DIABETIC MICE
DOI:
https://doi.org/10.69656/pjp.v19i4.1618Keywords:
Diabetes Mellitus, Walnut leaf, HbA1C, DapagliflozinAbstract
Background: With a rising prevalence of type 2 diabetes mellitus its becoming more important than ever to find new strategies to prevent and cure the disease. Objective of this study was to assess the effects of walnut leaves extract on the efficacy of dapagliflozin in type 2 diabetic mice. Methods: It was experimental, randomized control study. A total of 50 male Balb/c mice were included in this study and randomly divided into two groups: Group 1 (Normal Control) consisting of 10 mice and Group 2 (experimental group) of 40 mice. The experimental group was further divided into 4 groups of 10 mice each following induction of type 2 diabetes: Group 2 (Disease Control), Group 3 (Ethanolic walnut leaves extract treated), Group 4 (Dapagliflozin treated) and Group 5 (Combination of dapagliflozin and ethanolic walnut leaves extract treated) for a duration of 45 days. Statistical analysis was done using SPSS-27. One-way ANOVA (post hoc Tukey test) was used to compare the means of HbA1c among groups, and p<0.05 was considered significant. Results: Mice treated with walnut leaves extract (Group 3), dapagliflozin (Group 4), and the combination of walnut leaves extract and dapagliflozin (Group 5) exhibited significantly reduced serum HbA1c levels compared to those observed in the diabetic control group (p<0.05). Conclusions: The combined administration of walnut leaves extract and dapagliflozin leads to a significant decrease in serum HbA1c levels in diabetic mice, as compared to mice treated with walnut leaves extract or dapagliflozin alone.
Pak J Physiol 2013;19(4):26?8
Downloads
References
Demir S, Nawroth PP, Herzig S, Ekim Üstünel B. Emerging Targets in Type 2 Diabetes and Diabetic Complications. Adv Sci (Weinh) 2021;8(18):e2100275.
Castellani LN, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S, et al. Antipsychotics impair regulation of glucose metabolism by central glucose. Mol Psychiatry 2022;27:4741–53.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 2019;157:107843.
Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: A silent killer. Ann Med Surg (Lond) 2022;79:103901.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, et al. First-line therapy for type 2 diabetes with odium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A cost-effectiveness study. Ann Intern Med 2022;175(10):1392–400.
Ghusn W, Hurtado MD, Acosta A. Weight-centric treatment of type 2 diabetes mellitus brief running title: Clinical review of weight-centric diabetes treatments. Obesity Pillars 2022;4:100045.
Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab 2020;22 Suppl 1(Suppl 1):46–54.
Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. Clin J Am Soc Nephrol 2022;17(5):663–71.
Bhardwaj A, Singh A, Patnaik RS, Bhardwaj S. Juglans Regia L: A review of its traditional uses phytochemistry and therapeutic applications. J Pharm Negative Results 2023;14(1):11–6.
Rahman MM, Islam MR, Shohag S, Hossain ME, Rahaman MS, Islam F, et al. The Multifunctional Role of Herbal Products in the Management of Diabetes and Obesity: A Comprehensive Review. Molecules 2022;27(5):1713.
Xu Y, Tang G, Zhang C, Wang N, Feng Y. Gallic acid and diabetes mellitus: Its association with oxidative stress. Molecules 2021;26(23):7115.
Hashemi SS, Khaksar Z, Tadjalli M, Research P. Morphometric study of the effect of Walnut (Juglans regia) leaf extract on cerebrum malformation in fetuses of diabetic rats. J Chem Pharma Res 2015;7(2):441–5.
Azhar R, Ali S, Khan Hf, Farooq F, Noureen F, Anjam AF. Effect of ethanolic extract of walnut leaves on lipid profile and atherogenic index in hypercholesterolemic rats.Pak J Med Health Sci 2021;15(12):3955–8.
Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high?fat diet and multiple low?dose streptozocin (MLDS) mouse model of diabetes. J Pharm Pharmacol 2008;60(9):1167–73.
Nasiry D, Khalatbary AR, Ahmadvand H, Talebpour Amiri F, Akbari E. Protective effects of methanolic extract of Juglans regia L. leaf on streptozotocin-induced diabetic peripheral neuropathy in rats. BMC Complement Altern Med 2017;17(1):476.
Wei R, Cui X, Feng J, Gu L, Lang S, Wei T, et al. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metabolism 2020;111:154324.
Rato L, Alves MG, Dias TR, Cavaco JE, Oliveira PF. Testicular Metabolic Reprogramming in Neonatal Streptozotocin-Induced Type 2 Diabetic Rats Impairs Glycolytic Flux and Promotes Glycogen Synthesis. J Diabetes Res 2015;2015:973142
Wang JY, Zhu C, Qian TW, Guo H, Wang DD, Zhang F, et al. Extracts of black bean peel and pomegranate peel ameliorate oxidative stress-induced hyperglycemia in mice. Exp Ther Med 2015;9(1):43–8.
Asgary S, Parkhideh S, Solhpour A, Madani H, Mahzouni P, Rahimi P. Effect of ethanolic extract of Juglans regia L. on blood sugar in diabetes-induced rats. J Med Food 2008;11(3):533–8.
Chang DY, Li XQ, Chen M, Zhao MH. Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice. Front Pharmacol 2021;12:729334.
Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, et al. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother 2018;103:59–66.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.
